Literature DB >> 29500241

Statistical Validation of Rare Complement Variants Provides Insights into the Molecular Basis of Atypical Hemolytic Uremic Syndrome and C3 Glomerulopathy.

Amy J Osborne1, Matteo Breno2, Nicolo Ghiringhelli Borsa3, Fengxiao Bu3,4, Véronique Frémeaux-Bacchi5, Daniel P Gale6, Lambertus P van den Heuvel7,8, David Kavanagh9,10, Marina Noris2, Sheila Pinto11, Pavithra M Rallapalli1, Giuseppe Remuzzi2,12, Santiago Rodríguez de Cordoba11, Angela Ruiz11, Richard J H Smith3, Paula Vieira-Martins5, Elena Volokhina7, Valerie Wilson13, Timothy H J Goodship10, Stephen J Perkins14.   

Abstract

Atypical hemolytic uremic syndrome (aHUS) and C3 glomerulopathy (C3G) are associated with dysregulation and overactivation of the complement alternative pathway. Typically, gene analysis for aHUS and C3G is undertaken in small patient numbers, yet it is unclear which genes most frequently predispose to aHUS or C3G. Accordingly, we performed a six-center analysis of 610 rare genetic variants in 13 mostly complement genes (CFH, CFI, CD46, C3, CFB, CFHR1, CFHR3, CFHR4, CFHR5, CFP, PLG, DGKE, and THBD) from >3500 patients with aHUS and C3G. We report 371 novel rare variants (RVs) for aHUS and 82 for C3G. Our new interactive Database of Complement Gene Variants was used to extract allele frequency data for these 13 genes using the Exome Aggregation Consortium server as the reference genome. For aHUS, significantly more protein-altering rare variation was found in five genes CFH, CFI, CD46, C3, and DGKE than in the Exome Aggregation Consortium (allele frequency < 0.01%), thus correlating these with aHUS. For C3G, an association was only found for RVs in C3 and the N-terminal C3b-binding or C-terminal nonsurface-associated regions of CFH In conclusion, the RV analyses showed nonrandom distributions over the affected proteins, and different distributions were observed between aHUS and C3G that clarify their phenotypes.
Copyright © 2018 by The American Association of Immunologists, Inc.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29500241      PMCID: PMC6324840          DOI: 10.4049/jimmunol.1701695

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  75 in total

1.  Comprehensive genetic analysis of complement and coagulation genes in atypical hemolytic uremic syndrome.

Authors:  Fengxiao Bu; Tara Maga; Nicole C Meyer; Kai Wang; Christie P Thomas; Carla M Nester; Richard J H Smith
Journal:  J Am Soc Nephrol       Date:  2013-09-12       Impact factor: 10.121

2.  Power and sample size calculations. A review and computer program.

Authors:  W D Dupont; W D Plummer
Journal:  Control Clin Trials       Date:  1990-04

3.  A Familial C3GN Secondary to Defective C3 Regulation by Complement Receptor 1 and Complement Factor H.

Authors:  Sophie Chauvet; Lubka T Roumenina; Sarah Bruneau; Maria Chiara Marinozzi; Tania Rybkine; Elizabeth C Schramm; Anuja Java; John P Atkinson; Jean Claude Aldigier; Frank Bridoux; Guy Touchard; Veronique Fremeaux-Bacchi
Journal:  J Am Soc Nephrol       Date:  2015-10-15       Impact factor: 10.121

4.  Human C3 mutation reveals a mechanism of dense deposit disease pathogenesis and provides insights into complement activation and regulation.

Authors:  Rubén Martínez-Barricarte; Meike Heurich; Francisco Valdes-Cañedo; Eduardo Vazquez-Martul; Eva Torreira; Tamara Montes; Agustín Tortajada; Sheila Pinto; Margarita Lopez-Trascasa; B Paul Morgan; Oscar Llorca; Claire L Harris; Santiago Rodríguez de Córdoba
Journal:  J Clin Invest       Date:  2010-09-13       Impact factor: 14.808

Review 5.  Rare and common variants: twenty arguments.

Authors:  Greg Gibson
Journal:  Nat Rev Genet       Date:  2012-01-18       Impact factor: 53.242

6.  Complement gene variants determine the risk of immunoglobulin-associated MPGN and C3 glomerulopathy and predict long-term renal outcome.

Authors:  Paraskevas Iatropoulos; Marina Noris; Caterina Mele; Rossella Piras; Elisabetta Valoti; Elena Bresin; Manuela Curreri; Elena Mondo; Anna Zito; Sara Gamba; Serena Bettoni; Luisa Murer; Veronique Fremeaux-Bacchi; Marina Vivarelli; Francesco Emma; Erica Daina; Giuseppe Remuzzi
Journal:  Mol Immunol       Date:  2016-02-16       Impact factor: 4.407

7.  Complement mutations in diacylglycerol kinase-ε-associated atypical hemolytic uremic syndrome.

Authors:  Daniel Sánchez Chinchilla; Sheila Pinto; Bernd Hoppe; Marta Adragna; Laura Lopez; Maria Luisa Justa Roldan; Antonia Peña; Margarita Lopez Trascasa; Pilar Sánchez-Corral; Santiago Rodríguez de Córdoba
Journal:  Clin J Am Soc Nephrol       Date:  2014-08-18       Impact factor: 10.614

8.  Rare variant association studies: considerations, challenges and opportunities.

Authors:  Paul L Auer; Guillaume Lettre
Journal:  Genome Med       Date:  2015-02-23       Impact factor: 11.117

9.  Analysis of protein-coding genetic variation in 60,706 humans.

Authors:  Monkol Lek; Konrad J Karczewski; Eric V Minikel; Kaitlin E Samocha; Eric Banks; Timothy Fennell; Anne H O'Donnell-Luria; James S Ware; Andrew J Hill; Beryl B Cummings; Taru Tukiainen; Daniel P Birnbaum; Jack A Kosmicki; Laramie E Duncan; Karol Estrada; Fengmei Zhao; James Zou; Emma Pierce-Hoffman; Joanne Berghout; David N Cooper; Nicole Deflaux; Mark DePristo; Ron Do; Jason Flannick; Menachem Fromer; Laura Gauthier; Jackie Goldstein; Namrata Gupta; Daniel Howrigan; Adam Kiezun; Mitja I Kurki; Ami Levy Moonshine; Pradeep Natarajan; Lorena Orozco; Gina M Peloso; Ryan Poplin; Manuel A Rivas; Valentin Ruano-Rubio; Samuel A Rose; Douglas M Ruderfer; Khalid Shakir; Peter D Stenson; Christine Stevens; Brett P Thomas; Grace Tiao; Maria T Tusie-Luna; Ben Weisburd; Hong-Hee Won; Dongmei Yu; David M Altshuler; Diego Ardissino; Michael Boehnke; John Danesh; Stacey Donnelly; Roberto Elosua; Jose C Florez; Stacey B Gabriel; Gad Getz; Stephen J Glatt; Christina M Hultman; Sekar Kathiresan; Markku Laakso; Steven McCarroll; Mark I McCarthy; Dermot McGovern; Ruth McPherson; Benjamin M Neale; Aarno Palotie; Shaun M Purcell; Danish Saleheen; Jeremiah M Scharf; Pamela Sklar; Patrick F Sullivan; Jaakko Tuomilehto; Ming T Tsuang; Hugh C Watkins; James G Wilson; Mark J Daly; Daniel G MacArthur
Journal:  Nature       Date:  2016-08-18       Impact factor: 49.962

10.  Thrombomodulin mutations in atypical hemolytic-uremic syndrome.

Authors:  Mieke Delvaeye; Marina Noris; Astrid De Vriese; Charles T Esmon; Naomi L Esmon; Gary Ferrell; Jurgen Del-Favero; Stephane Plaisance; Bart Claes; Diether Lambrechts; Carla Zoja; Giuseppe Remuzzi; Edward M Conway
Journal:  N Engl J Med       Date:  2009-07-23       Impact factor: 91.245

View more
  53 in total

Review 1.  CFHR Gene Variations Provide Insights in the Pathogenesis of the Kidney Diseases Atypical Hemolytic Uremic Syndrome and C3 Glomerulopathy.

Authors:  Peter F Zipfel; Thorsten Wiech; Emma D Stea; Christine Skerka
Journal:  J Am Soc Nephrol       Date:  2020-01-24       Impact factor: 10.121

2.  Targeting properdin in the treatment of atypical haemolytic uraemic syndrome: better than eculizumab?

Authors:  Kate Smith-Jackson; Kevin J Marchbank
Journal:  Ann Transl Med       Date:  2018-11

3.  Complement Gene Variants and Shiga Toxin-Producing Escherichia coli-Associated Hemolytic Uremic Syndrome: Retrospective Genetic and Clinical Study.

Authors:  Véronique Frémeaux-Bacchi; Anne-Laure Sellier-Leclerc; Paula Vieira-Martins; Sophie Limou; Theresa Kwon; Annie Lahoche; Robert Novo; Brigitte Llanas; François Nobili; Gwenaëlle Roussey; Mathilde Cailliez; Tim Ulinski; Georges Deschênes; Corinne Alberti; François-Xavier Weill; Patricia Mariani; Chantal Loirat
Journal:  Clin J Am Soc Nephrol       Date:  2019-01-23       Impact factor: 8.237

4.  The use of eculizumab in Capnocytophaga canimorsus associated thrombotic microangiopathy: a case report.

Authors:  Magnus Holter Bjørkto; Andreas Barratt-Due; Ingvild Nordøy; Christina Dörje; Eivind Galteland; Andreas Lind; Abdulkarim Hilli; Pål Aukrust; Geir Mjøen
Journal:  BMC Infect Dis       Date:  2021-02-01       Impact factor: 3.090

Review 5.  Complementopathies and precision medicine.

Authors:  Eleni Gavriilaki; Robert A Brodsky
Journal:  J Clin Invest       Date:  2020-05-01       Impact factor: 14.808

Review 6.  C3 glomerulopathy - understanding a rare complement-driven renal disease.

Authors:  Richard J H Smith; Gerald B Appel; Anna M Blom; H Terence Cook; Vivette D D'Agati; Fadi Fakhouri; Véronique Fremeaux-Bacchi; Mihály Józsi; David Kavanagh; John D Lambris; Marina Noris; Matthew C Pickering; Giuseppe Remuzzi; Santiago Rodriguez de Córdoba; Sanjeev Sethi; Johan Van der Vlag; Peter F Zipfel; Carla M Nester
Journal:  Nat Rev Nephrol       Date:  2019-03       Impact factor: 28.314

7.  Large-Scale Whole-Genome Sequencing Reveals the Genetic Architecture of Primary Membranoproliferative GN and C3 Glomerulopathy.

Authors:  Adam P Levine; Melanie M Y Chan; Omid Sadeghi-Alavijeh; Edwin K S Wong; H Terence Cook; Sofie Ashford; Keren Carss; Martin T Christian; Matthew Hall; Claire Louise Harris; Paul McAlinden; Kevin J Marchbank; Stephen D Marks; Heather Maxwell; Karyn Megy; Christopher J Penkett; Monika Mozere; Kathleen E Stirrups; Salih Tuna; Julie Wessels; Deborah Whitehorn; Sally A Johnson; Daniel P Gale
Journal:  J Am Soc Nephrol       Date:  2020-01-09       Impact factor: 10.121

8.  Hemolytic uremic syndrome in a developing country: Consensus guidelines.

Authors:  Arvind Bagga; Priyanka Khandelwal; Kirtisudha Mishra; Ranjeet Thergaonkar; Anil Vasudevan; Jyoti Sharma; Saroj Kumar Patnaik; Aditi Sinha; Sidharth Sethi; Pankaj Hari; Marie-Agnes Dragon-Durey
Journal:  Pediatr Nephrol       Date:  2019-04-15       Impact factor: 3.714

9.  The Benefits of Complement Measurements for the Clinical Practice.

Authors:  Anne Grunenwald; Lubka T Roumenina
Journal:  Methods Mol Biol       Date:  2021

Review 10.  Thrombotic microangiopathy in aHUS and beyond: clinical clues from complement genetics.

Authors:  Fadi Fakhouri; Véronique Frémeaux-Bacchi
Journal:  Nat Rev Nephrol       Date:  2021-05-05       Impact factor: 28.314

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.